Search
moricizine (Ethmozine)
Tradename: Ethmozine. Class Ib antiarrhythmic agent.
Indications:
1) ventricular arrhythmias
2) not effective in treatment of supraventricular arrhythmias
3) not proven effective in preventing recurrence of sustained life-threatening ventricular arrhythmias
Dosage: 200-300 mg PO TID.
Tabs: 200, 250, 300 mg.
Adverse effects:
1) proarrhythmic effects (3%)
2) gastrointestinal
a) nausea & vomiting
b) diarrhea
3) central nervous system
a) tremor
b) mood changes
c) headache
d) vertigo
e) dizziness
f) nystagmus
Drug interactions:
- Morizine may decrease levels of theophylline. Hepatic metabolites eliminated by renal route (40%).
Interactions
drug interactions
General
antiarrhythmic agent, Group IB
Properties
MISC-INFO: elimination route LIVER 99%
pregnancy-category B
safety in lactation ?
Database Correlations
PUBCHEM cid=34633
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Manual of Medical Therapeutics, 28th ed, Ewald &
McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 156.